A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)

Michael D Greenwood,1 Richard A Gorham,2 Keeley R Boever2,3 1Vance Thompson Vision, West Fargo, ND, USA; 2Ektropia Solutions LLC, Laguna Beach, CA, USA; 3Vance Thompson Vision, Sioux Falls, SD, USACorrespondence: Michael D GreenwoodVance Thompson Vision, 505 32nd Ave E, Suite B, West Fargo, ND 58078...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Greenwood MD, Gorham RA, Boever KR
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/b3c2dc83a438462b8c6e84b15d70b8d3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:b3c2dc83a438462b8c6e84b15d70b8d3
record_format dspace
spelling oai:doaj.org-article:b3c2dc83a438462b8c6e84b15d70b8d32021-12-02T12:13:54ZA Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)1177-5483https://doaj.org/article/b3c2dc83a438462b8c6e84b15d70b8d32020-08-01T00:00:00Zhttps://www.dovepress.com/a-randomized-fellow-eye-clinical-trial-to-evaluate-patient-preference--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Michael D Greenwood,1 Richard A Gorham,2 Keeley R Boever2,3 1Vance Thompson Vision, West Fargo, ND, USA; 2Ektropia Solutions LLC, Laguna Beach, CA, USA; 3Vance Thompson Vision, Sioux Falls, SD, USACorrespondence: Michael D GreenwoodVance Thompson Vision, 505 32nd Ave E, Suite B, West Fargo, ND 58078, USATel +1 701-566-5390Fax +1 701-639-7199Email Michael.Greenwood@VanceThompsonVision.comPurpose: To determine the preference of patients undergoing bilateral LASIK for either the dexamethasone intracanalicular insert or topical prednisolone acetate for control of postoperative symptoms and ocular surface signs.Methods: In this randomized clinical trial, one eye was randomized to receive the dexamethasone insert or topical prednisolone acetate 1% four times daily for one week and 2 times daily for a second week; the fellow eye received the alternate therapy. One month postoperatively, patient preference for these two therapies was assessed using an adapted COMTOL questionnaire. Ocular comfort was assessed using the SPEED questionnaire. Corneal staining and uncorrected distance visual acuity (UDVA) were also assessed.Results: Twenty patients participated. At Month 1, 80% of patients preferred the dexamethasone insert, 10% preferred prednisolone acetate, and 10% expressed no preference (p< 0.001). SPEED scores measuring ocular comfort/discomfort related to dry eye symptoms were similar between groups (p=0.72), and both the incidence of patient-reported ocular dryness and the corneal staining scores were similar between groups. Both groups attained the same final UDVA.Conclusion: Patients undergoing elective bilateral femtosecond LASIK surgery overwhelmingly (by an 8-to-1 margin) preferred the dexamethasone insert to topical prednisolone acetate for postoperative treatment. The insert produced comparable ocular comfort, corneal staining, and visual acuity outcomes to topical prednisolone. The insert is an appropriate means of postoperative symptom control in this quality of life-conscious population.Keywords: dexamethasone, Dextenza, LASIK, randomized trial, patient preference, ocular surface symptomsGreenwood MDGorham RABoever KRDove Medical Pressarticledexamethasonedextenzalasikrandomized trialpatient preferenceocular surface symptomsOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 2223-2228 (2020)
institution DOAJ
collection DOAJ
language EN
topic dexamethasone
dextenza
lasik
randomized trial
patient preference
ocular surface symptoms
Ophthalmology
RE1-994
spellingShingle dexamethasone
dextenza
lasik
randomized trial
patient preference
ocular surface symptoms
Ophthalmology
RE1-994
Greenwood MD
Gorham RA
Boever KR
A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)
description Michael D Greenwood,1 Richard A Gorham,2 Keeley R Boever2,3 1Vance Thompson Vision, West Fargo, ND, USA; 2Ektropia Solutions LLC, Laguna Beach, CA, USA; 3Vance Thompson Vision, Sioux Falls, SD, USACorrespondence: Michael D GreenwoodVance Thompson Vision, 505 32nd Ave E, Suite B, West Fargo, ND 58078, USATel +1 701-566-5390Fax +1 701-639-7199Email Michael.Greenwood@VanceThompsonVision.comPurpose: To determine the preference of patients undergoing bilateral LASIK for either the dexamethasone intracanalicular insert or topical prednisolone acetate for control of postoperative symptoms and ocular surface signs.Methods: In this randomized clinical trial, one eye was randomized to receive the dexamethasone insert or topical prednisolone acetate 1% four times daily for one week and 2 times daily for a second week; the fellow eye received the alternate therapy. One month postoperatively, patient preference for these two therapies was assessed using an adapted COMTOL questionnaire. Ocular comfort was assessed using the SPEED questionnaire. Corneal staining and uncorrected distance visual acuity (UDVA) were also assessed.Results: Twenty patients participated. At Month 1, 80% of patients preferred the dexamethasone insert, 10% preferred prednisolone acetate, and 10% expressed no preference (p< 0.001). SPEED scores measuring ocular comfort/discomfort related to dry eye symptoms were similar between groups (p=0.72), and both the incidence of patient-reported ocular dryness and the corneal staining scores were similar between groups. Both groups attained the same final UDVA.Conclusion: Patients undergoing elective bilateral femtosecond LASIK surgery overwhelmingly (by an 8-to-1 margin) preferred the dexamethasone insert to topical prednisolone acetate for postoperative treatment. The insert produced comparable ocular comfort, corneal staining, and visual acuity outcomes to topical prednisolone. The insert is an appropriate means of postoperative symptom control in this quality of life-conscious population.Keywords: dexamethasone, Dextenza, LASIK, randomized trial, patient preference, ocular surface symptoms
format article
author Greenwood MD
Gorham RA
Boever KR
author_facet Greenwood MD
Gorham RA
Boever KR
author_sort Greenwood MD
title A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)
title_short A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)
title_full A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)
title_fullStr A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)
title_full_unstemmed A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)
title_sort randomized fellow-eye clinical trial to evaluate patient preference for dexamethasone intracanalicular insert or topical prednisolone acetate for control of postoperative symptoms following bilateral femtosecond laser in site keratomileusis (lasik)
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/b3c2dc83a438462b8c6e84b15d70b8d3
work_keys_str_mv AT greenwoodmd arandomizedfelloweyeclinicaltrialtoevaluatepatientpreferencefordexamethasoneintracanalicularinsertortopicalprednisoloneacetateforcontrolofpostoperativesymptomsfollowingbilateralfemtosecondlaserinsitekeratomileusislasik
AT gorhamra arandomizedfelloweyeclinicaltrialtoevaluatepatientpreferencefordexamethasoneintracanalicularinsertortopicalprednisoloneacetateforcontrolofpostoperativesymptomsfollowingbilateralfemtosecondlaserinsitekeratomileusislasik
AT boeverkr arandomizedfelloweyeclinicaltrialtoevaluatepatientpreferencefordexamethasoneintracanalicularinsertortopicalprednisoloneacetateforcontrolofpostoperativesymptomsfollowingbilateralfemtosecondlaserinsitekeratomileusislasik
AT greenwoodmd randomizedfelloweyeclinicaltrialtoevaluatepatientpreferencefordexamethasoneintracanalicularinsertortopicalprednisoloneacetateforcontrolofpostoperativesymptomsfollowingbilateralfemtosecondlaserinsitekeratomileusislasik
AT gorhamra randomizedfelloweyeclinicaltrialtoevaluatepatientpreferencefordexamethasoneintracanalicularinsertortopicalprednisoloneacetateforcontrolofpostoperativesymptomsfollowingbilateralfemtosecondlaserinsitekeratomileusislasik
AT boeverkr randomizedfelloweyeclinicaltrialtoevaluatepatientpreferencefordexamethasoneintracanalicularinsertortopicalprednisoloneacetateforcontrolofpostoperativesymptomsfollowingbilateralfemtosecondlaserinsitekeratomileusislasik
_version_ 1718394595219341312